Drugs / pulocimab
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04547205 | Jun 2020 → Mar 2021 | cancer | Akeso | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05142423 | Nov 2021 → Apr 2027 expected | — | Akeso | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04982276 | Aug 2021 → Dec 2025 overdue | gastroesophageal adenocarcinoma | Akeso | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06341335 | Jun 2024 → Nov 2026 expected | adenocarcinoma | Akeso | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-09-10 | Akeso | Results 卡度尼利联合方案治疗IO耐药 NSCLC 优异数据在WCLC口头报告发布 akesobio.com ↗
研究结果显示，IO耐药NSCLC患者接受卡度尼利联合方案治疗的总体获益明显，中位总生存期（mOS）为15.6个月，中位无进展生存期（mPFS）为5.8个月. |
| 2024-11-21 | Akeso | Results 沈琳教授谈胃癌一线治疗丨卡度尼利治疗一线胃癌全人群获益，开启胃癌免疫治疗2.0时代 akesobio.com ↗
II期研究结果显示出可控的安全性和令人鼓舞的疗效 |
| 2024-04-25 | Akeso | Results PD-1/VEGF双抗治疗nsq-NSCLC的III期研究结果将口头报告重磅发布丨ASCO 2024预告 akesobio.com ↗
研究结果显示，卡度尼利联合VEGFR-2单抗普络西具有显著的抗肿瘤活性和可控的安全性特征，有潜力解决对免疫疗法的耐药性问题，为经免疫检查点抑制剂联合化疗治疗进展的晚期胃癌患者的二线治疗提供更高效的治疗选择. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-09-10 | Akeso | 卡度尼利联合方案治疗IO耐药 NSCLC 优异数据在WCLC口头报告发布 akesobio.com ↗ |
| 2024-11-21 | Akeso | 沈琳教授谈胃癌一线治疗丨卡度尼利治疗一线胃癌全人群获益，开启胃癌免疫治疗2.0时代 akesobio.com ↗ |
| 2024-04-25 | Akeso | PD-1/VEGF双抗治疗nsq-NSCLC的III期研究结果将口头报告重磅发布丨ASCO 2024预告 akesobio.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pulocimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06341335 ↗ |
| Known as | AK109 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04547205 ↗ |
| Modality | Monoclonal antibody | “novel anti-VEGFR2 monoclonal antibody” PMID 36989884 ↗ Mar 2023 |
| Route | Intravenous | “AK109, 2#4#8#12#18mg/kg, IV, every 2 weeks (Q2W), or 15 mg/kg every 3 weeks(Q3W)” NCT04547205 ↗ |